Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2000

View Archived Issues

Alcon to develop drop formulation of moxifloxacin

Genentech acquires rights to PSCA from UroGenesys

Genopoietic to become Avax subsidiary

GelTex receives U.S. approval for Welchol, initiates phase I study for antitoxin polymer

Idec Pharmaceuticals reports Q2 2000 results

DepoMed's Metformin GR gives positive multiple-dose phase I results

NeisVac-C meningococcal vaccine approved in U.K.

Cell Pathways and Glaxo Wellcome to study Aptosyn/Navelbine combination for NSCLC

Approval of new treatment for schizophrenia backed by FDA panel

Zambon and Sheffield submit IND for MSI-cromolyn

Boston Biomedica expands license agreement to include anti-HBV candidates

Rights to S. pneumoniae vaccine technology licensed to SB

Parecoxib at least equieffective to ketorolac in the relief of dental pain

BoNT-B demonstrates significant efficacy in pain associated with cervical dystonia

Beneficial effects described at World Congress on Heart Failure for enrasentan in SHRSP-HSHF model

Advances in gene therapy for preventing restenosis reported in Vancouver

Myocet successfully substitutes for doxorubicin in CHOP therapy of AIDS-related lymphomas

Complete inhibition of HCMV replication obtained on combination regimens

First regulatory approval obtained for Migard

Major European market launches for Enbrel

Selectin modulators and their use described in recent patent by Ontogen and Organon

Antimicrobial hygromycin A derivatives in development at Pfizer

Sumitomo describes new compounds for cardiovascular disorders

New ACAT inhibitors patented in Japan particularly useful as antiatherosclerotics

SB presents new inhibitors of a cell cycle-regulating kinase

Potassium channel-activating smooth muscle relaxants designed by AHP

AstraZeneca describes new P2T receptor antagonists useful as antithrombotics

NeoPharm seeks clearance to begin clinical development of LE-AON

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...